Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc.（GBT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · GBT · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
4
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Global Blood Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
GBT 季度内部人买卖趋势
GBT 内幕交易卖出 · GBT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
GBT 高管卖出股份 · GBT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Sep 28, 2022 | JOHNSON DAVID LEE Chief Commercial Officer | Gift | 22,000 | — | Form 4 |
| Oct 1, 2022 | Habibizad Nazila See Remarks | Option | 182 | — | Form 4 |
| Oct 1, 2022 | Habibizad Nazila See Remarks | Option | 1,375 | — | Form 4 |
| Sep 29, 2022 | Habibizad Nazila See Remarks | Gift | 3,500 | — | Form 4 |
| Sep 27, 2022 | Farrow Jeffrey S CFO | Option | 23,653 | $388K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 83 | $4K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 1,027 | $50K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 2,043 | $122K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 3,005 | $89K | Form 4 |
| Sep 27, 2022 | Habibizad Nazila See Remarks | Option | 23,597 | $306K | Form 4 |
| Sep 9, 2022 | LOVE TED W President and CEO · Director | Gift | 221,200 | — | Form 4 |
| Sep 27, 2022 | LOVE TED W President and CEO · Director | Option | 18,291 | $300K | Form 4 |
| Sep 13, 2022 | LOVE TED W President and CEO · Director | Gift | 35,300 | — | Form 4 |
| Sep 13, 2022 | LOVE TED W President and CEO · Director | Gift | 17,650 | — | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 2,674 | $9K | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 2,674 | $9K | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 74,964 | $255K | Form 4 |
| Sep 29, 2022 | Choi Jung See Remarks | Gift | 73,855 | — | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 2,275 | $150K | Form 4 |
| Sep 27, 2022 | Choi Jung See Remarks | Option | 16,902 | $277K | Form 4 |
| Sep 1, 2022 | Habibizad Nazila See Remarks | Option | 2,208 | — | Form 4 |
| Sep 1, 2022 | Habibizad Nazila See Remarks | Other | 1,342 | $91K | Form 4 |
| Sep 1, 2022 | Habibizad Nazila See Remarks | Award | 414 | $11K | Form 4 |
| Sep 1, 2022 | JOHNSON DAVID LEE Chief Commercial Officer | Option | 2,208 | — | Form 4 |
| Sep 1, 2022 | JOHNSON DAVID LEE Chief Commercial Officer | Other | 2,103 | $143K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 GBT 内幕交易
GBT 内幕交易
Global Blood Therapeutics, Inc.（GBT）内幕交易数据来源于公司内部人（包括GBT）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。GBT内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Global Blood Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
GBT 内幕交易 · 5个问题Global Blood Therapeutics, Inc.（GBT）的内部人包括高管和董事，如GBT等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026